AL amyloidosis is a plasma cell disorder in which tissue deposition of immunoglobulin light chains leads to organ dysfunction. Recent reports of high-dose therapy with autologous stem cell transplantation for amyloidosis suggest higher response rates and extended survival compared to those seen with conventional chemotherapy. However, substantial treatment-related toxicity has been observed. This case series describes our institutional experience with autologous transplantation in four patients with amyloidosis with an emphasis on unique gastrointestinal toxicities, including toxic megacolon. Bone Marrow Transplantation (2002) 30, 279-285. doi:10.1038/sj.bmt.1703627 Keywords: AL amyloidosis; high-dose chemotherapy; stem cell transplantation; toxic megacolon AL amyloidosis is monoclonal plasma cell disorder characterized by tissue deposition of immunoglobulin light chains, leading to dysfunction of organs including the heart, kidneys, gastrointestinal (GI) tract, liver, soft tissues and nerves. In one series of 474 patients, the median survival after diagnosis was 13.2 months without treatment.
with autologous transplantation in patients with amyloidosis and focuses on the complication of toxic megacolon.
Patients and methods
Four patients received high-dose therapy and autologous stem cell transplantation at Oregon Health and Science University. Two patients were treated for primary AL amyloidosis, one for multiple myeloma with AL amyloidosis, and one patient for multiple myeloma who was later found to have AL amyloidosis (see details in Table 1 ).
Patient 1
A 57-year-old man presented with 18 months of progressive hand and finger swelling, nail changes, and skin fragility. His history was also notable for macroglossia with obstructive sleep apnea, and bilateral carpal tunnel release surgeries. A skin biopsy confirmed AL amyloid deposition. Serum protein electrophoresis (SPEP) did not reveal a monoclonal protein, but a bone marrow biopsy showed 16% lambda-restricted plasma cells without evidence of amyloid deposition and a 24 h urine collection showed 800 mg of Bence-Jones proteinuria. No lytic lesions were identified on bone survey.
The patient was treated with vincristine, adriamycin, and dexamethasone (VAD) chemotherapy, followed by cyclophosphamide, etoposide and decadron (CED) chemotherapy and G-CSF stem cell mobilization by which 37.3 ϫ 10 6 CD34 + cells/kg were collected and cryopreserved. Six months after the initiation of primary therapy, the patient received high-dose therapy with busulfan 4 mg/kg four times a day for 3 days, melphalan 50 mg/m 2 daily for 2 days, and thiotepa 250 mg/m 2 daily for 2 days, followed by autologous transplant with 19.3 ϫ 10 6 CD34 + cells/kg. The duration of severe neutropenia was 10 days, complicated by fever and grade 3 mucositis (NCI scale 17 ). Within 2 weeks of transplant, the patient had responded with near complete resolution of macroglossia and dermopathy. On day +14, he developed watery diarrhea, which responded to treatment with tincture of opium and pulsed steroids for possible autologous graft-versus-host disease. 18 However, on day +18, the diarrhea returned with frank hematochezia. Assays for ova and parasites, bacterial and viral pathogens, and C. difficile toxin were negative. Colonoscopy revealed ulceration and biopsies showed changes consistent with chronic ischemic colitis and focal amyloid deposition in vessel walls ( Figure 1 ). The patient received red cell and platelet transfusion support with gradual recovery, and was discharged on day +25. He was re-admitted on day +28 with fever and dehydration. Blood cultures revealed a coagulase-negative Staphylococcal species, which was treated with intravenous antibiotics and removal of his central catheter. The fevers persisted and he developed abdominal cramping with watery diarrhea and distention of the bowel of up to 8 cm on radiographs. He was treated with narcotic withdrawal, bowel rest, intravenous fluids, and additional empiric antibiotics. A tagged WBC scan showed persistent tracer activity in the distal transverse colon, but a CT scan showed only mild ascites without visible abscess formation. Again, multiple stool cultures and C. difficile toxin assays were negative. Over 1 week, his diarrhea slowed and he remained afebrile after stopping the antibiotics. On day +33, the patient developed new lower abdominal pain with urinary symptoms and was found to have adenoviral cystitis. With controlled diarrhea on bowel rest and total parenteral nutrition, he was discharged from the hospital on day +50, but continued to suffer persistent nausea and vomiting with any oral intake. On day +78, he developed acute jaundice and multiple new subcutaneous masses. He declined further treatment and died 81 days post transplant. A post-mortem examination was not performed.
Patient 2
A 51-year-old man presented with hypertension and proteinuria, which were treated medically. One year later, he noted intermittent nausea and vomiting with anorexia and an intervening 62-pound weight loss. He also complained of persistent lower extremity edema, easy bruising, decreased exercise tolerance, paresthesias in his feet, and several episodes of diarrhea lasting several days at a time. The serum creatinine was 1.9 mg/dl. A 24 h urine collection revealed a creatinine clearance of 80 ml/min and pro-teinuria of 12.9 g. Renal biopsy showed negative Congo red staining, but positive staining of mesangial deposits with anti-lambda light chain antibodies. Electron microscopy revealed fibrillary glomerular deposits with ultrastructural features and dimensions consistent with amyloid. A bone marrow biopsy demonstrated normal cellularity and composition with aggregates of small eosinophilic nodules which stained positively with Congo red and were faintly birefringent, consistent with amyloid. There was no detectable monoclonal protein in serum or urine. He had palpable hepatomegaly and an isolated elevation of the serum alkaline phosphatase. An echocardiogram showed normal myocardial wall thickness and normal systolic function. Several months after diagnosis, he underwent primary stem cell mobilization with G-CSF with a poor collection, followed by repeat mobilization with combination G-CSF and GM-CSF by which 6.5 ϫ 10 6
CD34
+ cells/kg were collected. The patient proceeded to high-dose therapy 1 month later, receiving melphalan 200 mg/m 2 , followed by autologous transplant. On admission, his creatinine had increased to 3.0 mg/dl. His early post-transplant course was marked by neutropenic fever and grade 3 mucositis. On day +5, he developed oliguric renal failure. A renal ultrasound showed echogenic kidneys without signs of obstruction and an echocardiogram was normal. Therapy with aggressive diuretics, albumin infusions, and low-dose dopamine did not control progressive volume overload, and on day +7 he was transferred to the intensive care unit for initiation of continuous veno-venous hemofiltration (CVVH). His course was complicated by hypotension requiring vasopressor support and new onset atrial fibrillation with rapid ventricular response. The patient's mental status deteriorated, and, with worsening mucositis, he was intubated for airway protection. Right heart catheterization showed a decreased systemic vascular resistance and elevated cardiac output consistent with sepsis. He developed new fevers, worsening hypotension, and increasing bilateral pulmonary infiltrates, co-incidental with neutrophil recovery. An abdominal source of the sepsis was suspected, with progressive abdominal distention with rigidity and dilated loops of bowel up to 6 cm on abdominal radiographs. Cultures failed to demonstrate an infectious pathogen and despite broad-spectrum antibiotics, the patient's multiorgan failure progressed. He was supported with antibiotics, vasopressors, CVVH, mechanical ventilation, and total parenteral nutrition with no improvement. On day +20, support was withdrawn and the patient expired. A post-mortem examination was not performed.
Patient 3
A 56-year-old man was evaluated for nephrosis with renal insufficiency. A renal biopsy showed active chronic interstitial nephritis with eosinophilia and interstitial hemorrhage. Electron microscopy findings were nondiagnostic with an inflammatory infiltrate in the interstitium. An SPEP revealed a monoclonal kappa light chain, a UPEP confirmed presence of Bence-Jones proteins, and a subsequent bone marrow biopsy showed large aggregates of plasma cells with 17% of these showing kappa-restriction. The
Bone Marrow Transplantation patient received therapy for multiple myeloma with oral melphalan and prednisone. Three years later, after rising serum paraprotein levels, he was treated with VAD chemotherapy and achieved only a partial response followed by three cycles of intermediate-dose cyclophosphamide, which reduced his bone marrow involvement to 11% plasma cells. He underwent hematopoietic stem cell mobilization using CED chemotherapy with G-CSF, and 8.3 ϫ 10 6 CD34
+ cells/kg were harvested by leukopheresis. Four years from initial diagnosis, he received high-dose therapy with busulfan 4 mg/kg in divided daily doses for 2 days, thiotepa 200 mg/m 2 daily for 2 days, and total body irradiation (TBI) 1.5 cGy twice daily for 3 days, followed by autologous stem cell transplantation. At the time of transplantation, the serum creatinine was 1.1 mg/dl. Post transplant, the patient developed severe mucositis and gastrointestinal bleeding, requiring transfusion support. He developed a neutropenic fever on day +1, and was empirically covered with broad-spectrum antibiotics until neutrophil recovery on day +10. Blood and urine cultures remained negative. On day +11, he suffered new abdominal cramping, nausea with vomiting, and increased diarrhea. His abdomen was firm and distended with mild diffuse tenderness, and an abdominal X-ray revealed up to 10 cm dilation of the ascending and transverse colon without obvious obstruction (Figure 2 ). This complication was treated with narcotic withdrawal, bowel rest and decompression by a nasogastric tube. By day +12, he became newly febrile and was restarted on broad-spectrum antibiotics. A colonoscopy revealed edematous and friable mucosa with a granular appearance and multiple ulcerations. Colonic biopsies revealed the presence of bi-refringent material in association with the muscularis mucosa, consistent with amyloidosis and mucosal changes secondary to local amyloidrelated vasculopathy. Assays for ova and parasites, bacterial and viral pathogens, and C. difficile toxin were repeatedly negative. The patient required continuous hospitalization with continued bowel dysfunction, abdominal distention, and return of fevers when off antibiotics. He was discharged from the hospital on day +76 post transplant, but continued to have abnormal abdominal radiographs for another 2 months. Two repeat colonoscopy exams showed similar findings. Retrospective analysis of pre-transplant bone marrow biopsies and a pre-transplant colon polyp and duodenal biopsy all failed to demonstrate involvement with amyloid, but a bone marrow examination prior to hospital discharge did show amyloid deposits.
After discharge, he required 6 additional weeks of parenteral nutrition, and by 10 months post transplant he continued to suffer poor appetite with weight loss. Twelve months post transplant, he developed increased urinary Bence-Jones protein with a stable serum creatinine of 0.9 mg/dl, followed by recurrent pleural transudates of unclear etiology. Ultimately, the patient died 14 months after transplantation with sepsis after an attempted pleurodesis. A post-mortem examination was not performed.
Patient 4
A 62-year-old man experienced progressive tongue swelling. Within 1 year, he was treated for obstructive sleep apnea with uvuloplasty and continuous positive airway pressure nocturnal ventilation. He also developed carpal tunnel syndrome and had bilateral surgical releases. He complained of easy bruising including periorbital ecchymoses, and stiffness with skin thickening of the cheeks, shoulders, and hands leading to the inability to tie his own shoes. An oral biopsy confirmed the presence of submucosal AL amyloid deposition. The serum creatinine was 0.8 mg/dl, total protein 4.7 g/dl, albumin 3.2 g/dl, and SPEP negative for a monoclonal protein. A 24 h urine collection showed 984 mg of mostly lambda Bence-Jones protein. No lytic lesions were found on bone survey. A bone marrow biopsy showed normal cellularity with 10-15% lambda-restricted plasma cells, and no evidence of amyloid deposition. An echocardiogram showed mild left atrial enlargement and normal left ventricular function. There were no specific findings to suggest a restrictive myopathic process. After diagnosis, the patient was treated with three cycles of VAD chemotherapy, followed by stem cell mobilization with cyclophosphamide and G-CSF, and 41.8 ϫ 10 6
CD34
+ cells/kg were collected. This chemotherapy was complicated by neutropenic fever and paroxysmal atrial fibrillation. A repeat echocardiogram showed no myocardial abnormalities to suggest amyloid infiltration.
One month later, he underwent high-dose therapy with melphalan 200 mg/m 2 followed by autologous stem cell transplantation. His post-transplantation course was complicated by severe neutropenia for 10 days, anemia and thrombocytopenia requiring transfusion support, grade 3 mucositis, and culture-negative neutropenic fever covered with broad-spectrum antibiotics. He did not experience any further tachyarrhythmias.
Two months post-transplantation, a bone marrow biopsy revealed no amyloid deposits but persistent disease with 5-10% lambda-restricted plasma cells, and he was started on maintenance therapy with thalidomide 100 mg daily. By 13 months post transplantation, his proteinuria had continued to decrease to 117 mg in 24 h and his bone marrow showed similar findings. The patient reported significant improvement in tongue swelling and body stiffness. He had returned to his normal activities.
Discussion
In this series of four patients who received high-dose therapy and autologous stem cell transplantation, two were treated for primary AL amyloidosis, one for multiple myeloma with AL amyloidosis, and one patient was later found to have AL amyloidosis complicating multiple myeloma ( Table 1 ). Two of the four patients died within 3 months of transplantation, one of multi-organ system failure and one of probable progressive disease in the setting of significant colitis. Of the two patients surviving Ͼ100 days, one had severe colitis with megacolon and biopsy-proven amyloid-related vasculopathy, later dying with relapse and infection. Both patients surviving the transplantation procedure had partial hematologic and amyloid-involved organ disease remissions.
Several groups have reported on the use of high-dose therapy with autologous stem cell transplantation in treating AL amyloidosis (Table 2 ). In total, these results would suggest response rates of approximately 50%. However, the total observed rate of 100 day treatment-related mortality was 18%, without stratification based on organs affected by amyloid. In contrast, toxic death rates of only 5% after autologous transplantation are typical for patients with multiple myeloma. [19] [20] [21] While the data for amyloidosis may be skewed by selective case reporting of adverse events, outcomes in the largest series show similar mortality rates. Early deaths are often from cardiac causes or multi-organ failure.
Substantial morbidity has also been reported after highdose therapy in patients with amyloidosis, including a few published reports detailing substantial GI toxicity. In 1992, Mehta et al 22 described a case of massive GI bleeding 3 days after an abbreviated course of high-dose therapy and allogeneic transplantation for multiple myeloma with amyloidosis of the bowel. In an autologous transplantation series, Dember et al 9 observed mucositis in 53%, elevation in liver enzymes or bilirubin levels in 13%, and GI bleeding in 10% of 65 patients. A fatal case of gastrointestinal perforation with amyloid infiltration occurring 4 days after autologous transplantation was reported by Schulenburg et al. 23 Gertz et al 8, 10 described GI toxicity in five of 20 patients (25%) surviving autologous transplantation, with four requiring prolonged enteral and/or parenteral nutrition including one with severe gastrointestinal bleeding. Comenzo et al 24 stated 'the degree of gastrointestinal toxicity with 200 mg/m 2 of melphalan is striking,' with nausea and vomiting in 83%, diarrhea in 65%, mucositis in 91%, and GI bleeding in 22% of patients. In reviewing the use of autologous transplantation for amyloidosis, Sanchorawala et al 11 agreed that 'pretransplant assessment of gastrointestinal function and mucosal integrity has been essential'.
The GI toxicities observed at our institution included not only severe mucositis and GI bleeding, but also clinical presentations of toxic megacolon, with non-obstructive colonic dilatation, fever and other signs of systemic toxicity. 25 The degree of toxicity was severe. One patient was considered for total colectomy and another had persistent bowel dysfunction for nearly 5 months. These patients did not have a history of underlying inflammatory bowel disease and no infectious causes for the colitis were identified. Biopsies revealed acute inflammation consistent with toxic megacolon, but were also notable for focal vascular amyloid deposition and associated mucosal injury. In the nonBone Marrow Transplantation transplantation setting, amyloid deposition can lead to a variety of GI symptoms, and has been associated with spontaneous bowel perforation 26 and fatal GI hemorrhage. 27 Pathophysiologically, amyloid infiltration may directly contribute to the generation of toxic megacolon by injuring the mucosa and by impairing the smooth muscle and myenteric nerve plexus needed to maintain normal gut motility. In patient 1, the early, rapid, and marked regression of macroglossia may have reflected systemic decreases in GI tissue infiltration, leading to thinning of the gut wall and contributing to mucosal breakdown. Other potential factors contributing to the development of toxic megacolon in this group of patients include the use of vincristine in pre-transplantation therapy, and the use of thiotepa in the conditioning regimen, both of which may be toxic to the autonomic nerves controlling gut motility. 28 In addition to treatment-related GI toxicities, other organ systems may be substantially compromised after high-dose therapy in patients with amyloidosis. Multiple investigators have documented episodes of profound renal and cardiac insufficiency, with edema, volume overload, and vascular leak syndromes. 4, 5, 8, 9, 12, 29 This description is similar to the course of patient 2 in our series. Cardiac arrhythmias and sudden death are also relatively frequent in this patient population. 4, 5, 8, 9, 12, 13, 29 A retrospective analysis of 21 patients revealed that the number of clinical manifestations of amyloidosis pre-transplantation was predictive for survival, with a toxic death rate of Ͼ75% in patients with two or more organ dysfunctions. 5 In addition to the number of affected organ systems, the presence of symptomatic cardiac involvement has statistically correlated with poorer overall survival rates. 24 The high rates of toxicity observed with high-dose therapy for primary amyloidosis have led to questions about the impact of amyloidosis on outcomes in patients undergoing autologous transplantation for multiple myeloma. In a series of 84 myeloma patients, no differences were found in disease characteristics, event-free survival, or overall survival in the 38% found to have amyloid deposits. 30 However, these findings have been criticized because most of the patients with documented amyloidosis were discovered after routine subcutaneous fat pad aspirates, with only seven biopsies of symptomatic organs. Saba et al 29 noted fatal arrhythmias and refractory stem cell infusion-related hypotension occurring in six of nine patients transplanted for predominantly cardiac AL amyloidosis, but in none of over 100 patients transplanted for myeloma.
Based on the high degree of toxicity observed, clinicians must remain critical when evaluating the role of high-dose therapy and autologous transplantation in treating amyloidosis. The long-term survival with stem cell transplantation is not yet known, and the population found to be eligible might have relatively 'good risk' amyloidosis, including extended survival without transplantation. In a retrospective analysis of patients seen at the Mayo Clinic from 1983 to 1997, the median survival of the 229 patients who would have met standard eligibility criteria for transplantation was 42 months. 31 In conclusion, high-dose therapy and autologous stem cell transplantation is feasible in a selected subset of patients with AL amyloidosis, with generation of hematologic and amyloid-involved organ disease remissions. Previous authors have identified patients with involvement of fewer than two symptomatic organ systems and no cardiac pathology as benefiting most from this treatment. 19, 24 However, based on the experiences outlined above, particular attention to the presence of GI involvement with amyloidosis appears prudent, as significant morbidity and mortality has been documented in these patients. Careful review of prior GI symptoms is fundamental to pre-transplantation evaluations to identify those at risk for intestinal amyloid. Other strategies to detect amyloid may include routine radiographs or rectal biopsies, in which abnormalities may be found even in asymptomatic patients. 26, 27 However, the clinical utility is limited by lack of available data to assess an individual's transplantation risk based on positive rectal biopsies without symptoms. Finally, clinicians should be aware of toxic megacolon as a potential complication of high-dose therapy in amyloidosis.
